Recent developments include quarterly earnings call highlights and transcripts providing updates on ZEVASKYN® commercialization, manufacturing challenges, and pipeline progress.

• Abeona Therapeutics reported Q2 2026 earnings call highlights discussing commercial launch progress and manufacturing challenges for ZEVASKYN® [N1].
• Q1 2026 earnings transcripts detailed ongoing efforts to expand qualified treatment centers and address manufacturing issues [N2][N3].
• Q4 2025 earnings call transcript provided insights into initial commercial activities and regulatory milestones [N4].
• Pre-market earnings report for March 17, 2026, included Abeona among companies with recent financial disclosures [N5].

Abeona’s successful commercialization of ZEVASKYN® addresses a significant unmet medical need in RDEB, a rare and debilitating genetic skin disease. The product’s demonstrated durable wound healing and pain reduction in clinical trials support its therapeutic value. The company’s established manufacturing capabilities and expanding qualified treatment center network facilitate patient access. Broad insurance coverage and a permanent CMS J-code enhance reimbursement prospects. Abeona’s pipeline of novel gene therapies using AIM™ capsids targets additional rare diseases with high unmet needs, potentially expanding its therapeutic portfolio.

Manufacturing and quality control challenges for ZEVASKYN® have caused delays in product release and could continue to impact supply reliability. The complexity of autologous cell therapy production presents risks related to scalability, regulatory compliance, and cost. The company reported a net loss and has not disclosed revenue figures, indicating ongoing financial pressures. Market adoption depends on successful expansion of treatment centers and payer acceptance. Pipeline programs are in early stages, with preclinical or IND-enabling activities, and face typical development and regulatory risks.

Abeona’s moat is anchored in its FDA-approved autologous cell-based gene therapy ZEVASKYN®, which is the first and only approved treatment for wounds in RDEB patients. The company’s proprietary manufacturing platform and cGMP facility provide commercial-scale production capabilities. Its network of qualified treatment centers and broad insurance coverage, including CMS and Medicaid, support market access. Additionally, Abeona’s AIM™ capsid technology platform and pipeline of gene therapies for rare ophthalmic diseases contribute to its competitive positioning. Regulatory designations such as Orphan Drug and Rare Pediatric Disease status confer market exclusivity and potential benefits.

• Manufacturing Complexity and Supply Risks: ZEVASKYN® manufacturing involves complex processes with risks of production interruptions, quality control failures, and regulatory compliance challenges. Recent batches faced release delays due to sterility and cellular identity test issues, impacting commercial supply [S2].
• Financial Performance and Liquidity: The company reported a net loss of $20.19 million for Q2 2026 and has not disclosed revenue, indicating ongoing financial challenges. However, it maintains strong liquidity with $56.2 million cash and equivalents and a current ratio of 6.63 as of June 30, 2026 [S2].
• Market Adoption and Reimbursement: Commercial success depends on expanding the qualified treatment center network and securing payer coverage. While broad insurance coverage and a CMS J-code exist, adoption in a rare disease market may be gradual [S1].
• Pipeline Development Risks: Gene therapy programs for ophthalmic diseases are in preclinical or early development stages, with timelines delayed due to focus on ZEVASKYN® commercialization. These programs face typical clinical and regulatory risks [S1].

• Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases [S1].
• The company’s lead product, ZEVASKYN® (prademagene zamikeracel), is the first and only FDA-approved autologous cell-based gene therapy for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) [S1].
• ZEVASKYN® was approved by the FDA on April 28, 2025, and has Orphan Drug, Rare Pediatric Disease, Regenerative Medicine Advanced Therapy (RMAT), and Breakthrough Therapy designations [S1].
• ZEVASKYN® is manufactured at Abeona’s cGMP facility in Cleveland, Ohio, and treatments are administered through a network of qualified treatment centers, with four centers activated as of March 2026 [S1].
• The company began treating patients with ZEVASKYN® in Q4 2025 [S1].
• ZEVASKYN® commercialization strategy focuses on expanding qualified treatment centers and securing insurance coverage, including broad coverage from commercial insurers, CMS, and Medicaid programs across all US states and Puerto Rico [S1].
• CMS issued a permanent J-code for ZEVASKYN® effective January 1, 2026, to simplify claims and reimbursement processing [S1].
• Abeona’s pipeline includes AAV-based gene therapies for ophthalmic diseases using novel AIM™ capsids, including ABO-503 for X-linked Retinoschisis (XLRS), ABO-504 for Stargardt disease, and ABO-505 for Autosomal Dominant Optic Atrophy (ADOA) [S1].
• The company has established internal commercial-scale manufacturing capabilities and quality systems for cell and gene therapies [S1].
• Manufacturing ZEVASKYN® presents significant challenges, including complex production, quality control, and regulatory compliance issues, with recent manufacturing batches facing release delays due to sterility and cellular identity testing issues [S2].
• Abeona reported a net loss of $20.19 million and basic and diluted EPS of -$0.35 for the quarter ended June 30, 2026 [S2].
• As of June 30, 2026, Abeona had $56.2 million in cash and equivalents and a current ratio of 6.63, indicating strong liquidity [S2].
• The company sold a Rare Pediatric Disease Priority Review Voucher (PRV) for $155 million in mid-2025 to strengthen its cash position ahead of ZEVASKYN® launch [N8][N5].
• ZEVASKYN® demonstrated durable wound healing and pain reduction in clinical trials, including the pivotal VIITAL™ Phase 3 study, with no serious treatment-related adverse events reported [S1].
• The company is actively engaging with healthcare stakeholders, including hospitals, insurers, patients, and physicians, to support ZEVASKYN® adoption [S1].
• Recent earnings call highlights and transcripts provide updates on commercial launch progress, manufacturing challenges, and pipeline development [N1][N2][N3][N4].